EP2691367A1 - Réactifs d'alkylation électrophiles, leur préparation et leur utilisation - Google Patents

Réactifs d'alkylation électrophiles, leur préparation et leur utilisation

Info

Publication number
EP2691367A1
EP2691367A1 EP12708364.0A EP12708364A EP2691367A1 EP 2691367 A1 EP2691367 A1 EP 2691367A1 EP 12708364 A EP12708364 A EP 12708364A EP 2691367 A1 EP2691367 A1 EP 2691367A1
Authority
EP
European Patent Office
Prior art keywords
bromide
phenyl
methyl
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12708364.0A
Other languages
German (de)
English (en)
Inventor
Emilia Perpetua Tavares Leitao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hovione Inter AG
Original Assignee
Hovione Inter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovione Inter AG filed Critical Hovione Inter AG
Publication of EP2691367A1 publication Critical patent/EP2691367A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/12—Sulfonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/06—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function

Definitions

  • Electrophilic alkylating reagents their preparation and use
  • Alkylation is the transfer of an alkyl group from one molecule to another.
  • the alkyl group may be transferred as an alkyl carbocation, a free radical, a carbanion or a carbene (or their equivalents) .
  • Alkylating agents are widely used in chemistry because the alkyl group is probably the most common group encountered in organic molecules.
  • Many biologically active target molecules, or their synthetic precursors contain one or more specific functional groups with a given order of reactivity. Selective alkylation, or addition to a desired functional group, is used, especially if there is no commonly available precursor already containing the alkyl group.
  • Alkylating agents are classified according to their nucleophilic or electrophilic character [ (a) Jerry March, 1985, Advanced Organic Chemistry reactions, mechanisms and structure, 3rd ed; (b) Stefanidakis, G. ; Gwyn, J.E. 1993, "Alkylation", In John J. Mc etta. Chemical Processing Handbook)].
  • Methyl iodide (and others alkyl halides) are carcinogenic [(a) Pokier, L. A.; Stoner, G. D.; Shimkin, M. B. Cancer Res. 1975, 35, 1411. (b) Mc Cann, J.; Choi, E.; Yamasaki, E. ; Ames, B. N. Proc. Nati. Acad. Sci. U.S.A. 1975, 72, 5135].
  • Dimethyl ⁇ sulfate is especially dangerous, is extremely hazardous liquid and its vapor causes burns to lungs and tissues, and may be fatal if inhaled.
  • Dimethyl carbonate has been shown to be environmental friendly [(a) Memoli S, Selva M, Tundo P. Chemosphere 2001, 43, 115. (b) Tundo, P.; Selva, M. Acc. Chem. Res. 2002, 35, 706-716]. In the presence of potassium carbonate and DBU it is especially reactive, one use being to alkylate phenols [Shieh, W.-C; Dell, S.; Repic, 0. J. Org. Chem.
  • Tetramethylantmonium salts are another type of alkylating agents, considered to be non- carcinogenic and non-volatile, but with very low reactivity-
  • diazo compounds such as diazomethane and trimethylsilyldiazomethane (TMSD) .
  • Methylation is the most common type of alkylation, being associated with the transfer of a methyl group.
  • Bromomethane also called methyl bromide
  • methyl bromide is a favored, reagent used in methylations to prepare tertiary amines or quaternary ammonium salts present in the structure of biologically active compounds such as, but not limited to: demecarium bromide, fenpiverinium bromide, fentonium bromide, heteronium bromide, mepenzolate bromide, tropenziline bromide, vecuronium bromide, propantheline bromide, timepedium bromide, pancuronium bromide, penthienate bromide, pipecuronium bromide, pipenzolate bromide, tiotropium bromide, anisotropine methylbromide, hexafluorenium bromide, ipratropium bromide, 8-p-phenyl
  • steroids such as: (10R, 13S, 17 ) -methyl 11, 17-dihydroxy-lO, 13-dimethyl- 3-0X0-6,7,8,9,10,11,12,13,14,15,16, . 17-dodecahydro-3H- cyclopenta [a] phenanthrene-17-carboxylate .
  • Bromomethane ⁇ is a volatile compound with a high mixing rate in the atmosphere. Bromomethane escapes easily into the atmosphere where it contributes to the depletion of ozone. It works similarly to CFCs in its reaction with ozone molecules (0 3 ) . In the stratosphere UV light from the Sun catalyses the break down of methyl bromide forming elemental bromine which reacts with ozone, thus " depleting the ozone layer. Bromomethane is 60 times more destructive to stratospheric ozone than chlorine. As such, it is subject to phase-out requirements of the 1987 Montreal Protocol on Ozone Depleting Substances (ODS) .
  • ODS Ozone Depleting Substances
  • the literature also refers to another methylating. reagent, methyldiphenilsulfonium (Formula I) which has been isolated as a triflate salt (J. Am. Chem. Soc. 1993, 115, 5819-5820), a perclorate salt (Hinsberg; Chemische Berichte; vol. 69, 1936; p. 94), a hexafluorophosphate salt (Beak, Peter; Sulivan, Thomas A.; Journal of the American Chemical Society; vol. 104; nb. 16, 1982; p. 4450 - 4457) and as a tetrafluoroborate salt, the latter of which is commercially available.
  • this compound is prepared using the methylating reagents referred to as hazards or ODS. Therefore, there is a need for alternative reagents to carry out methylations, and other alkylations in general.
  • the present invention provides new electrophilic alkylation reagents which can be converted into several salts and can successfully quaternize amines, yielding their tetrafluororate or triflate or eventually bromide or other salts, by ionic change. These reagents can also be used tor the alkylation of oxygen, sulfur and phosphorous atoms.
  • the compounds of the invention are solid and are not harmful to the ozone layer.
  • This invention aims to avoid the use of reagents that deplete the ozone layer or are hazardous by offering alternative reagents to carry out alkylation reactions that are less problematic in their use.
  • j. is an aryl group
  • R 2 is an alkyl group
  • R 3 is a substituted phenyl group, wherein the number of substituents (n) is greater than 2;
  • R 4 is an anion; preferably tetrafluoroborate, triflate, sulfate, phosphate or carbonate.
  • Ri is an optionally substituted C 6 -i2 aryl group and more preferably R x is an optionally substituted phenyl group, such as phenyl substituted by one or more Ci- 4 alkyl groups. Most preferably, R x is a phenyl or p-tolyl group.
  • R 2 is a linear or branched chain d-e alkyl group, more preferably a linear or branched chain Ci_ 6 alkyl group, and most preferably a linear or branched chain Ci- 4 alkyl group.
  • Preferred examples of R 2 include methyl, ethyl, n-propyl, iso- propyl, n-butyl, sec-butyl, iso-butyi and tert-butyl. More preferred examples of R2 include methyl and ethyl.
  • R 3 is a phenyl group substituted by two or more alkyl groups, preferably two or more linear or branched chain Ci-6 alkyl groups, and more preferably two or more linear or branched chain C1-4 alkyl groups.
  • Preferred alkyl group substituents include methyl, ethyl, n-propyl, iso-propyl, n- butyl, sec-butyl, iso-butyl and tert-butyl. More preferred alkyl group substituents include methyl and ethyl, particularly methyl.
  • (n) is 2, 3, 4 or 5. More preferably, (n) is 2, 3 or 4. Most preferably, (n) is 4.
  • R4 is tetrafluoroborate, triflate or hexfluorophosphate .
  • Ri is an alkyl group or H
  • R 2 is an alkyl group
  • R 3 , R 4 , R5, Re and R7 which may be the same or different, are each independently selected from an alkyl group or H; and e is an anion; preferably tetrafluoroborate, triflate, sulfate, phosphate or carbonate.
  • Ri is an alkyl group, it is preferably a linear or branched chain C 1 -4 alkyl group such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl or tert-butyl, most preferably methyl.
  • Ri is H.
  • R 2 is a linear or branched chain Ci- a alkyl group, more preferably a linear or branched chain Ci-6 alkyl group, and most preferably a linear or branched chain C1-4 alkyl group.
  • Preferred examples of R2 include methyl, ethyl " , n-propyl, iso- propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl. ' More preferred examples of R2 include methyl and ethyl.
  • R3, R 4 R 5 , R 6 and R 7 are H and each of the remaining substituents, which may be the same or different, is an alkyl group, preferably linear or branched chain Ci- 4 alkyl groups such as methyl, ethyl, n-propyl, iso-propyl, n- butyl, sec-butyl, iso-butyl or tert-butyl, particularly methyl.
  • each of R4, R5 and R6 which may be the same or different, is an alkyl group, preferably a linear or branched chain C1-4 alkyl group, and one of R3 and RT is H and the other is an alkyl group, preferably a linear or branched chain C1-4 alkyl group, particularly methyl.
  • each of R 3 , R4, 5 and R6 is an alkyl " group, preferably a linear or branched chain C1-4 alkyl group, particularly methyl, and RT is H.
  • R 8 is tetrafluoroborate, triflate or hexfluorophosphate .
  • Particularly preferred compounds of the present invention include :
  • Organic biologically active compounds can be obtained by the alkylation reaction between organic substrates with compounds of Formula II or preferably compounds of Formula III.
  • organic biologically active compounds we mean an organic compound which is of medical or therapeutic use in the broadest sense. Typically, the organic biologically active compounds are pharmaceutically active compounds.
  • alkylating reagents of this invention can be conveniently prepared in a one pot reaction, by isolating each intermediate or combining reactions and isolating only some of the intermediates.
  • Ri is an aryl group
  • R 2 is an alkyl group
  • R 3 is a substituted phenyl group, wherein the number of substituents (n) is greater than 2;
  • R 4 is a anion; preferably tetrafluoroborate) triflate, sulfate, phosphate or carbonate; which process comprises (i) reacting a compound of Formula IV,
  • Ri and R ⁇ are as defined in Formula II, with a suitable substituted phenyl derivative; (ii) reacting the compound so formed with a suitable anion source; and optionally thereafter (iii) converting one compound of Formula II into another.
  • Examples of suitable compounds of Formula IV include methyl phenyl sulfoxide and ethyl phenyl sulfoxide.
  • Compounds of Formula IV are commercially available or may be prepared from their corresponding sulphide precursors ⁇ such as methyl- or ethyl phenyl sulphide) using conventional methods known in the art, as exemplified by the methods of Examples I and 7 herein.
  • anion sources include trifluoromethanesulfonic anhydride, sodium tetrafluoroborate and hexafluorophosphoric acid. Such compounds are commercially available or may be prepared using conventional methods known in the art.
  • a ' process for preparing a compound of Formula II or Formula III which process comprises the step of preparing a compound of Formul-a V, VI or VII,
  • Ri f R 2 R3 / R and R 5 which may be the same or different, are independently selected from H, alkyl, aryl, alkoxy and halogen; R 6 is an alkyl group; and
  • R 12 is H, optionally substituted naphthalene or a polymer resin.
  • alkyl and aryl as used with reference to compounds of Formulae V, VI and VII have the same meanings as hereinbefore defined in with reference to compounds of Formula II.
  • alkoxy refers preferably to a linear or branched chain Ci-e alkoxy group, more preferably to a linear or branched chain Ci-t alkoxy group, and most preferably to a linear or branched chain C 1 -4 alkoxy group.
  • Preferred examples of alkoxy groups include methoxy, ethoxy, propoxy and butoxy.
  • halogen means F, CI, Br or I, preferably CI or Br.
  • Rx 2 represents substituted naphthalene
  • preferred examples include 1-methylnaphthalene and 2-methylnaphthalene.
  • Ri2 represents a resin
  • preferred examples include (Poly (styrene-co-diviny,lbenzene) and other benzenic resins.
  • the reactions to prepare compounds of Formulae II and III can be carried at a temperature in the range between from about - 70 °C to about 70 °C, preferably from about -10 °C to about 25 °C.
  • the reactions to prepare compounds of Formulae II and III are typically carried ouL in the presence of a suitable organic solvent.
  • suitable organic solvents include, but are not limited to, diethyl ether, dichloromethane and acetonitrile.
  • the reaction may also be carried out in the presence of an organic or inorganic catalyst.
  • suitable catalysts include, but are not limited to metallic catalysts, preferably transition metals and transition metal complexes.
  • the reactions can be carried out in the presence of other chemical compounds such as: oxidizing agents (such as oxygen peroxide) , reductive agents (such as hydrogen) , organic or inorganic bases and/or halogenating agents (such as thionyl chloride and phosphorus pentachloride) .
  • oxidizing agents such as oxygen peroxide
  • reductive agents such as hydrogen
  • organic or inorganic bases such as organic or inorganic bases and/or halogenating agents (such as thionyl chloride and phosphorus pentachloride)
  • halogenating agents such as thionyl chloride and phosphorus pentachloride
  • the compounds of Formulae II and III can be isolated- by direct crystallization from the reaction mixture; by the addition of an anti-solvent which can be an organic solvent or water, or water with acid, or water with base (or by the addition of water, or water with acid, or water with base to the reaction mixture) ; by extraction with organic solvent and/or concentration (organic layers can be washed with water, and/ or bases, and or acids, and or reductive agents and/or can be dried using a drying agents) ; by recrystallization in organic solvent; and/or by column chromatography. Resins and/ or activated charcoal can also be used during the work-up to purify the . alkylating reagent end-product.
  • an anti-solvent which can be an organic solvent or water, or water with acid, or water with base (or by the addition of water, or water with acid, or water with base to the reaction mixture)
  • organic solvent and/or concentration organic layers can be washed with water, and/ or bases, and or acids, and or re
  • the starting materials can be used either as described above (i.e. in "free form") or may be bound to a suitable solid phase support, such as a resin.
  • a suitable solid phase support such as a resin.
  • One aspect of this invention concerns methods for preparation of alkylated organic biologically active compounds using the alkylating reagents described above and/or and salts thereof.
  • the present invention provides the use of a compound of Formula II or Formula III, or a salt thereof, as an alkylating agent, preferably for the alkylation of an organic biologically active compound, such as a pharmaceutically active compound.
  • an organic biologically active compound comprising at least one alkylation step, wherein the alkylating reagent is a compound of Formula II or a salt thereof.
  • the alkylated organic biologically active compounds can be prepared by reaction of the alkylating reagents (of Formulae II and III) with a suitable substrate.
  • suitable substrates include, but are not limited to, N- Demethyltiotropium [ (Scopine di (2-thienyl) glycolate] or (10R, 13S, 17R) -11, 17-dihydroxy-10, 13-dimethyl-3-oxo-6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17-dodecahydro-3H-cyclopenta [a] phenanthrene- 17-carboxylic acid
  • the reactions to prepare alkylated organic biologically active compounds can be carried at a temperature in the range between from about -70 °C to about 70 °C, preferably from about -10 °C to about 25 °C.
  • Such reactions are typically carried out in the presence of a suitable organic solvent.
  • suitable solvents include, but are not limited to, acetonitrile, heptane, hexane, cyclohexane, methyl tert-butyl ether (MTBE) , dimethylformamide (D F) , toluene, 1, 2-dichloromethane, ⁇ , ⁇ , ⁇ -trifluorotoluene, tetrahydrofurane (THF) , methyl-THF, 1, 2-dimethoxyethane and mixtures thereof.
  • the reactions can also be carried out in the presence of an organic or inorganic catalyst such as preferably transition metals and transition metal complexes.
  • the reactions can also be carried out in the presence of other chemical compounds such as: oxidizing agents (such as oxygen peroxide), reductive agents (such as hydrogen), organic or inorganic bases (such as a weak base, in particular caesium carbonate, sodium carbonate, potassium carbonate and/ or mixtures thereof), and/or halogenating agents (such as thionyl chloride and Phosphorus pentachloride) .
  • oxidizing agents such as oxygen peroxide
  • reductive agents such as hydrogen
  • organic or inorganic bases such as a weak base, in particular caesium carbonate, sodium carbonate, potassium carbonate and/ or mixtures thereof
  • halogenating agents such as thionyl chloride and Phosphorus pentachloride
  • the alkylated organic biologically active compounds obtained can be isolated by crystallization from the reaction mixture or by addition of an anti-solvent to the reaction mixture.
  • the anti-solvent can be an organic solvent or water, water with acid or water with base.
  • the alkylated organic biologically active compounds can also be isolated by the addition of water to the reaction mixture (or water with acid, or water with base) . They can also be isolated by extraction with an organic solvent and/or concentration.
  • the organic layers can be washed with water and/ or base, and or acid, and or reductive agent solution. After or during the washes the organic layers can be dried with drying agents. Resin and activated charcoal can also be used during the workup to purify the organic extracts.
  • the alkylated organic biologically active compounds isolated from the reactions as described above can be purified by recrystallization or by column chromatography and can be isolated as a dry power by spray drying or lyophilisation.
  • alkylated organic biologically active compounds that may be prepared using the alkylating reagents of Formulae II and III include, but are not limited to: demecarium bromide, fenpiverinium bromide, fentonium bromide, heteronium bromide, mepenzolate bromide, tropenziline bromide, vecuronium bromide, propantheline bromide, timepedium bromide, pancuronium bromide, penthienate bromide, pipecuronium bromide, pipenzolate bromide, tiotrop um bromide, anisotropine methylbromide, hexafluorenium bromide, ipratropium bromide, 8-p-phenylbenzyltropinium bromide, oxitefonium bromide, and others .
  • the compounds to be prepared using alkylating reagents of Formulae II and III include: tiotropium bromide, anisotropine methylbromide, fenpiverinium bromide, fentonium bromide, hexafluorenium bromide, ipratropium bromide, 8-p-phenylbenzyltropinium bromide, most preferably tiotropium bromide and ipratropium bromide.
  • the alkylation reaction is especially suited to lower alkylation reactions and the organic biologically active compounds obtained are for example methylated or ethylated compounds.
  • the alkylation reaction of this invention is not limited only to the alkylation of nitrogen atoms but is also applicable to the alkylation of compounds at other heteroatoms, such as a sulfur atom as well an oxygen atom.
  • biologically active compounds that may be produced in this way include, but are not limited to, Etisul® (diethyldithioiisophthaiate) and Stimovul® (epimestrol) .
  • the alkylated organic biologically active compounds obtained can be used as active pharmaceutical ingredients, formulated as known and used in the treatment of several medical conditions .
  • MS were recorded in a LC - Waters Alliance 2690 with a PDA detector Waters 996; MS: Micromass, Quattro LC or in a LC - Waters Alliance 2695 with a PDA detector Waters 2996; MS: Micromass, Quattro micro
  • Methyl phenyl sulfide (18.9 mL, 159.42 mmol) was dissolved in dichloromethane (120 mL) and the solution was cooled to a temperature between 5 °C and 0 °C. A mixture of methanol (200 mL) and water (20 mL) was added to the previous solution. NBS (28.7 g, 1.01 eq) was added in small portions, maintaining the same temperature range. ' The reaction mixture was stirred within the same temperature range until the reaction was complete. Thereafter, the reaction mixture was quenched by the addition of Na 2 S0 3 solution (10%, 150 mL) . The pH of the reaction mixture was adjusted to a value between 7 and 8, with saturated NaHC0 3 solution.
  • Methyl phenyl sulfoxide (9.45 g, 67.40 mmol) was dissolved in dry diethyl ether (50 ml) under nitrogen atmosphere.
  • 1,2,3,4- Tetramethylbenzene (10.1 mL, 1.0 eq) was added to the previous solution and then the mixture was cooled to a temperature between 5 °C and 0 °C.
  • trifluoromethanesulfonic anhydride 11.36 mL, 1.0 eq
  • the mixture was stirred until the reaction was complete.
  • the precipitated triflate salt was isolated by filtration, washed with diethyl ether at 0 °C dried.
  • Methyl p-tolyl sulfoxide (1 g 6.48 mmol) was dissolved in dry diethyl ether (15 mL) under nitrogen atmosphere. 1,2,3,4- Tetramethylbenzene (0.92 ml, 1 eq) was added to the previous solution and then the reaction mixture was cooled to a temperature between -5 °C and -10 °C. After stabilizing the temperature, trifluoromethanesulfonic anhydride (1.3 mL, 1.2 eq) was added slowly, maintaining the same temperature. The mixture was stirred until the reaction was complete. The precipitated triflate salt was isolated by filtration, washed with diethyl ether at 0 °C and dried under vacuum.
  • Methyl ⁇ (2, 3, , 5-tetramethylphenyl) (p-tolyl) sulfonium trifluoromethahesulfonate (1.2 g) of example 4, was dissolved in dichloromethane (30 ml) . The solution was washed 6 times with a sodium tetrafluoroborate solution (IN) . The resulting organic layer was dried with anhydrous sodium sulfate and concentrated to dryness. 0.83 g of the desired product was obtained as a white solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des réactifs d'alkylation électrophiles représentés par la formule II dans laquelle R1 est un groupe aryle, R2 est un groupe alkyle, R3 est un groupe phényle substitué, le nombre des substituants (n) étant supérieur à 2 ; et R4 est un anion, ainsi que leurs sels. L'invention concerne également des méthodes de préparation de ces réactifs et des méthodes de préparation de composés alkylés biologiquement actifs utilisant ces réactifs.
EP12708364.0A 2011-03-28 2012-02-23 Réactifs d'alkylation électrophiles, leur préparation et leur utilisation Withdrawn EP2691367A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT105584A PT105584B (pt) 2011-03-28 2011-03-28 Reagentes electrofílicos de alquilação, a sua preparação e usos
PCT/GB2012/000189 WO2012131286A1 (fr) 2011-03-28 2012-02-23 Réactifs d'alkylation électrophiles, leur préparation et leur utilisation

Publications (1)

Publication Number Publication Date
EP2691367A1 true EP2691367A1 (fr) 2014-02-05

Family

ID=45815907

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12708364.0A Withdrawn EP2691367A1 (fr) 2011-03-28 2012-02-23 Réactifs d'alkylation électrophiles, leur préparation et leur utilisation

Country Status (4)

Country Link
EP (1) EP2691367A1 (fr)
CN (1) CN103502211A (fr)
PT (1) PT105584B (fr)
WO (1) WO2012131286A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI538902B (zh) * 2012-09-15 2016-06-21 羅門哈斯電子材料有限公司 鎓化合物及其合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100279497B1 (ko) * 1998-07-16 2001-02-01 박찬구 술포늄 염의 제조방법
EP0972761B1 (fr) * 1998-07-16 2001-12-12 Korea Kumho Petrochemical Co. Ltd. Sels de sulfonium et procédé pour leur préparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012131286A1 *

Also Published As

Publication number Publication date
CN103502211A (zh) 2014-01-08
PT105584A (pt) 2012-09-28
WO2012131286A1 (fr) 2012-10-04
PT105584B (pt) 2013-08-30

Similar Documents

Publication Publication Date Title
US9359294B2 (en) Electrophilic reagents for monohalomethylation, their preparation and their uses
KR20170086604A (ko) 스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
ES2841324T3 (es) Proceso para la 6,7-alfa-epoxidación de 4,6-dienos esteroideos
KR20170104453A (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
KR20170099895A (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
KR20170099896A (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
AU2010252609A1 (en) Novel glucocorticoid receptor agonists
JP2016523246A (ja) アルキルフルオロアルキルスルホネートによるアルキル化
NO751939L (fr)
EP2691367A1 (fr) Réactifs d&#39;alkylation électrophiles, leur préparation et leur utilisation
US9676815B2 (en) Process for the preparation of abiraterone or abiraterone acetate
CA2291438C (fr) Procede de nitration pour ethers diphenyliques
US20140171645A1 (en) Electrophilic alkylating reagents, their preparation and use
US20170088578A1 (en) Method for Monofluoromethylation of Organic Substrates to Prepare Biologically Active Organic Compounds
JP6646316B2 (ja) ヒドロキシ基及び／又はメルカプト基用保護基導入剤
EP3383832A1 (fr) Procédé pour la préparation de composés cannabinoïdes 3-substitués
EP0000152A1 (fr) Acides et esters oxaminiques, procédés pour leur préparation et compositions pharmaceutiques les contenant
JP2024529153A (ja) Δ９，１１ステロイドの合成
WO2018147345A1 (fr) Composé 15-oxostéroïde et procédé de production de celui-ci
WO2006038047A1 (fr) Procede non polluant de synthese d&#39;ammonio-steroides quaternaires
ITMI20111704A1 (it) Processo per la sintesi di fospropofol
ITMI20110580A1 (it) Iintermedi utili per la preparazione di fospropofol e processo per la loro preparazione
JPH0227995B2 (fr)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150615